2017
DOI: 10.4306/pi.2017.14.3.344
|View full text |Cite
|
Sign up to set email alerts
|

Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study

Abstract: Objectiveα-synuclein, Nogo-A and Ubiquitin C-terminal hydrolase L1 (UCH-L1) have neuromodulatory roles for human brain. Therefore, abnormalities of these molecules are associated with neuropsychiatric disorders. Although some serum studies in the other disorders have been made, serum study of α-synuclein, Nogo-A and UCH-L1 is not present in patients with schizophrenia and healthy controls. Therefore, our aim was to compare serum levels of α-synuclein, Nogo-A and UCH-L1 of the patients with schizophrenia and he… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
10
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(12 citation statements)
references
References 45 publications
0
10
0
Order By: Relevance
“…In addition, point mutations in the α-synuclein gene are known to be a risk factor for Parkinson’s disease 37. The association between α-synuclein expression and schizophrenia has been shown by a previous study 3839…”
Section: Introductionmentioning
confidence: 77%
“…In addition, point mutations in the α-synuclein gene are known to be a risk factor for Parkinson’s disease 37. The association between α-synuclein expression and schizophrenia has been shown by a previous study 3839…”
Section: Introductionmentioning
confidence: 77%
“…Whether alterations of this pathway are present in MS patients remains to be elucidated. Interestingly, several pathologies besides MS have been recently described to be associated with altered Nogo‐A levels, such as Alzheimer's disease and schizophrenia (Xu et al, 2015; Demirel et al, 2017); thus, patients with these diseases can benefit from the results of this study. Neutralization with anti‐Nogo‐A antibodies or inhibition of NgR1 with LINGO‐1 has already been evaluated in animal models and clinical trials for MS and show potential therapeutic effects (Ineichen et al, 2017).…”
Section: Discussionmentioning
confidence: 82%
“…47 Although a PPI deficit is in line with the observed striatal hyperdopaminergia and locomotor hyperactivity, the 2 phenotypes developed differently with time, that is, increased dopamine/activity emerged at 3 months and PPI at 9 months, suggesting that additional neurotransmitter systems or factors play a role. Finally, few reports have revealed a link between AS and psychosis, irrespective of PD, including an association between SNCA polymorphisms and methamphetamine-induced psychosis, 48 decreased serum AS levels in schizophrenic patients, 49 and less frequent AS Lewy pathology in chronic schizophrenia compared with age-matched healthy elderly people. 50 Noteworthy are the small cohorts used in these clinical studies.…”
Section: Discussionmentioning
confidence: 99%